Summary News Back
Rising awareness and media coverage of liver diseases, particularly PBC, including expert discussions and patient stories on various platforms.
Promising clinical trial results for new PBC treatments such as linerixibat, seladelpar (Livdelzi), and elafibranor (Iqirvo), showing improvements in symptoms like itch and fatigue.
Regulatory progress with multiple approvals and conditional authorizations of PBC treatments across Europe, the US, and the UK (e.g., Livdelzi, Iqirvo).
Ongoing research into the mechanisms and associated conditions of PBC, including links to lymphoma, systemic sclerosis, and gut microbiota.
Growing investment and milestone payments in the PBC drug development sector, reflecting commercial interest and expanding treatment options.
Studies highlighting the importance of early diagnosis, personalized treatment plans, and quality of life improvements for PBC patients.
Concerns over safety and effectiveness of existing treatments, with regulatory bodies declining or revoking approvals (e.g., Ocaliva).
Educational efforts through art, patient stories, and physician guidance to support awareness and understanding of rare liver diseases like PBC.
News Articles Back
05/12/2025 Primary Biliary Cholangitis Treatment Market to Reach US$2.72 - openPR.com
05/12/2025 Strength and Spirit: Anna’s Experience with a Rare Liver Disease - Reader's Digest
03/12/2025 Shifts in Blood Lipids Linked to Early Primary Biliary Cholangitis - European Medical Journal
01/12/2025 Diagnostic Potential of Salivary Biomarkers for Primary Biliary Cholangitis: A Systematic Review - Frontiers
28/11/2025 Pruritus Exhausts Patients With Primary Sclerosing Cholangitis - Medscape
27/11/2025 Altered sphingolipid profile in primary biliary cholangitis: associations with fibrosis and inflammation - Nature
26/11/2025 Transjugular intrahepatic portosystemic shunt for hepatic sinusoidal obstruction syndrome with primary biliary cholangitis and alcoholic liver disease: a case report - Frontiers
19/11/2025 Blood group A linked to a higher risk of primary biliary cholangitis - News-Medical
18/11/2025 Primary Biliary Cholangitis (PBC) Treatment Market to Reach USD 2.72 Billion by 2033, Driven by Next-Generation FXR Agonists & Immunomodulators | DataM Intelligence - PR Newswire
18/11/2025 Future of the Global Primary Biliary Cholangitis Market: Trends, Innovations, and Key Forecasts Through 2034 - openPR.com
13/11/2025 Seladelpar Eases PBC-Related Itch for 30 Months - MedPage Today
11/11/2025 Long-Term Efficacy and Symptom Relief With Elafibranor in PBC, With Andreas Kremer, MD, PhD - HCPLive
10/11/2025 Seladelpar Staves Off Liver Stiffness in PBC - Medscape
10/11/2025 Seladelpar’s Impact on Liver Stiffness Measurements in PBC, With Christopher Bowlus, MD - HCPLive
09/11/2025 Interim Data Support Elafibranor in Rare Chronic Liver Disease - MedPage Today
08/11/2025 Seladelpar’s Long-Term Benefit for Pruritus in PBC, With Gideon Hirschfield, FRCP, PhD - HCPLive
07/11/2025 Volixibat Improves Fatigue and Sleep in Patients With Primary Biliary Cholangitis - HCPLive
07/11/2025 Ipsen to present two late-breaking sessions at AASLD on new PBC data supporting IQIRVO®’s long-term efficacy, safety and mechanistic insights in fatigue - Yahoo Finance
07/11/2025 Gilead’s Livdelzi® Demonstrates Sustained Efficacy in Primary Biliary Cholangitis (PBC), Offering Alkaline Phosphatase (ALP) Reduction, Itch Relief and Potential to Slow Disease Progression - The AI Journal
05/11/2025 VIDEO: Scoring tools may help identify nonresponders in primary biliary cholangitis - Healio
30/10/2025 Seladelpar’s Impact on Pruritus in Primary Biliary Cholangitis, With Marlyn Mayo, MD - HCPLive
30/10/2025 Ipsen at The Liver Meeting 2025 - Ipsen
27/10/2025 Exploring primary biliary cholangitis - Healio
26/10/2025 Advancing the management of primary biliary cholangitis: From pathogenesis to emerging therapies - Baishideng Publishing Group
23/10/2025 Gilead to Showcase Interim Long-Term Efficacy Data for Livdelzi® (Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta - Yahoo Finance
21/10/2025 LYVDELZI® (SELADELPAR) RECEIVES HEALTH CANADA APPROVAL FOR THE TREATMENT OF PRIMARY BILIARY CHOLANGITIS - Newswire Canada
15/10/2025 Women with PBC may be at high risk of disease flares after childbirth - Liver Disease News
14/10/2025 Multi-omics tests identify novel shared genetic mechanisms of primary biliary cholestasis and sarcopenia - Nature
10/10/2025 Bezafibrate for primary biliary cholangitis: time to act on the evidence - Nature
09/10/2025 Beyond Ursodeoxycholic Acid: A Comprehensive Review of Second-Line Agents in Primary Biliary Cholangitis - Cureus
07/10/2025 Linerixibat Reduces Itching in PBC - Medscape
03/10/2025 Primary Biliary Cholangitis (PBC) Workup: Approach Considerations, Laboratory Studies, Imaging Studies - Medscape
01/10/2025 PBC worst for life quality among autoimmune liver diseases: Study - Liver Disease News
19/09/2025 Mixed Multiple Autoimmune Syndrome Type 3 With Coexistence of Primary Biliary Cholangitis, Inflammatory Myopathy, and Chronic Thyroiditis: A Case Report - Cureus
18/09/2025 PBC Awareness Day: Confronting Bias and Elevating Patient Voices - Ipsen
15/09/2025 Common pathological mechanisms and therapeutic strategies in primary Sjogren’s syndrome and primary biliary cholangitis: from tissue immune microenvironment to targeted therapy - Frontiers
15/09/2025 Navigating New PBC Therapies and Treatment Monitoring With Ann Moore, NP - HCPLive
12/09/2025 Liver Disease Drug Pulled From the Market - MedPage Today
11/09/2025 Ocaliva for PBC Withdrawn From US Market - Medscape
11/09/2025 Intercept Announces Voluntary Withdrawal of OCALIVA® for Primary Biliary Cholangitis (PBC) from the US Market; US Clinical Trials Involving Obeticholic Acid Placed on Clinical Hold - Yahoo Finance
11/09/2025 Intercept Voluntarily Withdraws Obeticholic Acid (Ocaliva) for PBC From US Market - HCPLive
10/09/2025 Gilead fashions new primary biliary cholangitis campaign alongside 'Project Runway' designer - Fierce Pharma
10/09/2025 September's PBC Awareness Month raises support for a rare liver... - Liver Disease News
08/09/2025 Progress in PBC, PSC: Key Updates in Cholestatic Liver Disease Care With Ann Moore, NP - HCPLive
05/09/2025 Innate immunity of bile and cholangiocytes in primary biliary cholangitis - Frontiers
29/08/2025 Zydus Therapeutics Reports Positive Topline Results from EPICS-III Phase 2(b)/3 Trial of Saroglitazar Magnesium in Patients with Primary Biliary Cholangitis - PR Newswire
27/08/2025 Local Woman Launches Support Group For People With Primary Biliary Cholangitis - The Citizen Newspaper Group
26/08/2025 An experimental study on the effect of symptom expectations on mental fatigue and motivation in people with primary biliary cholangitis | Scientific Reports - Nature
26/08/2025 Pruritus Increases HRQoL Burden in PBC, Underscoring Need for Effective Treatments - HCPLive
25/08/2025 Understanding PBC: Managing what Matters Most - Ipsen
06/08/2025 Adding Vitamin D boosts PBC treatment in clinical trial - Liver Disease News
03/08/2025 Research progress and perspectives of non-coding RNAs in primary biliary cholangitis: from mechanisms to therapeutics - Frontiers
23/07/2025 PPAR agonists effective in UDCA-resistant primary biliary cholangitis - Liver Disease News
17/07/2025 GSK’s Linerixibat Poised to Address Substantial Unmet Need for the Treatment of Pruritus Associated with Primary Biliary Cholangitis, According to Spherix Global Insights - Yahoo Finance
08/07/2025 Fulminant Primary Biliary Cholangitis-Autoimmune Hepatitis (PBC-AIH) Overlap Syndrome in a 27-Year-Old Woman With Childhood-Onset AIH: Steroid-Refractory Decompensation Necessitating Urgent Transplant Evaluation - Cureus
02/07/2025 Endothelial cells expressing CPE and vWF are involved in the Immunopathogenesis of primary biliary cholangitis - Nature
02/07/2025 Nearly half of PBC patients in US haven’t seen a specialist recently - Liver Disease News
02/07/2025 Hepatic Encephalopathy Induced by Small Bowel Obstruction in a Patient With Primary Biliary Cholangitis - Cureus
30/06/2025 Treatment of pruritus in primary biliary cholangitis - Clínica FEHV
27/06/2025 Gilead Art Campaign Captures The PBC Patient Experience, Inspires Patient-Centric Trials - Clinical Leader
25/06/2025 EMA to review linerixibat for itch in primary biliary cholangitis - Liver Disease News
23/06/2025 EU kicks off review of GSK's linerixibat in PBC - Pharmaphorum
20/06/2025 Novel Therapies for Primary Biliary Cholangitis - Medscape Reference
12/06/2025 Primary biliary cholangitis and the narrowing gap towards optimal disease control - The Lancet
04/06/2025 $2.27 Bn Primary Biliary Cholangitis Market Forecasts and - GlobeNewswire
04/06/2025 FDA Accepts GSKs NDA for First-in-Class IBAT Inhibitor Linerixibat to Treat Cholestatic Pruritus in Primary Biliary Cholangitis - Pharmaceutical Executive
19/05/2025 Double Trouble: Drug-Induced Autoimmune Hepatitis (AIH)-Primary Biliary Cholangitis (PBC) Overlap Syndrome Triggered by Hydralazine - Cureus
15/05/2025 Seladelpar Found Safe and Effective For Patients With PBC and Cirrhosis - Gastroenterology & Endoscopy News
14/05/2025 Livdelzi effective on primary biliary cholangitis, regardless of prior treatment - Liver Disease News
09/05/2025 Gilead’s Livdelzi Shows Lasting Efficacy in Primary Biliary Cholangitis, Regardless of Prior Therapy - Pharmaceutical Executive
09/05/2025 Linerixibat Demonstrates Statistically Significant Reduction in Pruritus in Phase III GLISTEN Trial for PBC - Applied Clinical Trials
08/05/2025 Iqirvo Shows Significant Fatigue Improvement in Patients with Primary Biliary Cholangitis After 52 Weeks in Phase III ELATIVE Trial - Applied Clinical Trials
08/05/2025 Sleep Disorders and PBC Disease Severity, with Ana Marenco Flores, MD - HCPLive
08/05/2025 Oral IBAT Inhibitor Improves Cholestatic Itch in Primary Biliary Cholangitis - MedPage Today
07/05/2025 Bringing PBC Into Focus Through Art of Patient Stories - Gilead Sciences
06/05/2025 Ipsen to present new data across four rare liver diseases at EASL, including late-breaking data in PBC and PSC - Ipsen
29/04/2025 Health Canada approves IQIRVO® as a first-in-class dual-peroxisome proliferator-activated receptor treatment for primary biliary cholangitis - BioSpace
29/04/2025 Biochemical and Plasma Lipid Responses to Pemafibrate in Patients With Primary Biliary Cholangitis and Dyslipidemia: A Four-Year Analysis - Cureus
25/04/2025 Ipsen’s elafibranor shows promise in rare liver disease primary sclerosing cholangitis - PMLiVE
23/04/2025 90% of People With This Rare Liver Disease Are Women—Meet the Patient Advocate Helping Empower Others - Flow Space
14/04/2025 Bibliometric analysis of research on intestinal flora and primary biliary cholangitis published between 2004 and 2024 using VOSviewer and CiteSpace visualization - Frontiers
10/04/2025 Systemic Sclerosis and Primary Biliary Cholangitis: A Comprehensive Review of Two Overlapping Rare Entities With Insights on Diagnostics and Management - Cureus
08/04/2025 Ipsen’s Iqirvo accepted by SMC to treat rare liver disease primary biliary cholangitis - PMLiVE
07/04/2025 The Scottish Medicines Consortium (SMC) accepts Ipsen’s IQIRVO® (elafibranor) for use in NHS Scotland – the first new medicine in nearly a decade for primary biliary cholangitis (PBC), a rare liver disease - Ipsen
04/04/2025 Autoimmune Hepatitis-Primary Biliary Cholangitis Overlap in a Case of Pulmonary Arterial Hypertension and Sjögren's Syndrome: Occam's Razor or Hickam's Dictum? - Cureus
26/03/2025 2nd-line PBC treatment options call for personalized care: Analysis - Liver Disease News
24/03/2025 Navigating Evolutions, Uncertainties in PBC Care, with Craig Lammert, MD - HCPLive
21/03/2025 The Evolving Primary Biliary Cholangitis Landscape, with Craig Lammert, MD - HCPLive
07/03/2025 A Rare Case of Concurrent Primary Biliary Cholangitis and Sarcoidosis - Cureus
07/03/2025 Autoimmune Gastritis Complicated by Primary Biliary Cholangitis: A Report of Two Cases and Literature Review - Cureus
26/02/2025 Seladelpar conditionally approved in European Union to help treat PBC - Liver Disease News
26/02/2025 Guidelines on the diagnosis and management of primary biliary cholangitis - EurekAlert!
24/02/2025 Breaking Grounds: A Comprehensive Analysis of Cutting-Edge Treatments for Primary Biliary Cirrhosis/Primary Biliary Cholangitis With Futuristic Treatments - Cureus
20/02/2025 EU okays Gilead's seladelpar for primary biliary cholangitis - FirstWord Pharma
17/02/2025 Primary Biliary Cholangitis in a Patient With Multiple Sclerosis: A Case Report - Cureus
13/02/2025 Elafibranor Increase Survival Primary Biliary Cholangitis Patients PBC - Gastroenterology & Endoscopy News
05/02/2025 Poor primary biliary cholangitis outcomes linked with two self-reactive antibodies - Liver Disease News
10/01/2025 Exploration of Novel Metabolic Mechanisms Underlying Primary Biliary Cholangitis Using Hepatic Metabolomics, Lipidomics, and Proteomics Analysis - ACS Publications
08/01/2025 FDA Grants Orphan Drug Designation to CNP-104 for Primary Biliary Cholangitis - HCPLive
28/12/2024 Development and external validation of an early prediction model to identify irresponsive patients and prognosis of UDCA treatment in primary biliary cholangitis - Nature
